SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-17-143300
Filing Date
2017-04-27
Accepted
2017-04-27 17:03:56
Documents
7
Effectiveness Date
2017-04-27

Document Format Files

Seq Description Document Type Size
1 DEFA14A d292940ddefa14a.htm DEFA14A 32622
2 GRAPHIC g292940notice1a.jpg GRAPHIC 11514
3 GRAPHIC g292940notice1b.jpg GRAPHIC 7906
4 GRAPHIC g292940notice1c.jpg GRAPHIC 7956
5 GRAPHIC g292940notice1d.jpg GRAPHIC 2400
6 GRAPHIC g292940notice1e.jpg GRAPHIC 3697
7 GRAPHIC g292940notice2a.jpg GRAPHIC 6650
  Complete submission text file 0001193125-17-143300.txt   90060
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Filer) CIK: 0000873303 (see all company filings)

IRS No.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-14895 | Film No.: 17790100
SIC: 2834 Pharmaceutical Preparations